UCSF Limited Submission Opportunities
(Applications through UCSF Limited Submission Program)
- Deadline: Dec 23 at noon
RFA-CA-24-030 NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
Purpose: to provide scientific leadership for developing and implementing multi-disciplinary, multi-institutional trials in a range of cancer types and special populations with specific scientific strategy and goals. - Deadline: Dec 23 at noon
RFA-CA-24-031 NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
Purpose: to provide the infrastructure for the conduct of national clinical trials through the National Clinical Trials Network (NCTN). - Deadline: Jan 10 at noon
Kleberg Medical Research Awards Spring 2025
Purpose: To fund highly innovative and groundbreaking proposals in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health.
Intramural Funding Opportunities
For questions about intramural awards, please contact Meredith Donnelly.
- Deadline: Jan 15, 2025
HDFCCC Bladder Cancer Research Hub RFA
The Bladder Cancer Research Hub is requesting applications from HDFCCC members for pilot research projects. Priority areas to be funded include: research addressing strategic goals of the Bladder Cancer Program (see RFA for details), cross-disciplinary research and investigators who have not previously collaborated, and projects addressing health disparities. - LOI Deadline: Jan 23, 2025
UC Cancer Research Coordinating Committee (CRCC) Faculty Seed Grants
CRCC Faculty Seed Grants support meritorious research spanning all areas from basic research to applied clinical and community-based research in any field relevant to cancer.
Foundations/Other Sources
- Deadline: Jan 6, 2025
NCCN Phase I/II Clinical Trials of Zipalertinib (CLN 081/TAS 6417) for Non-Small Cell Lung Cancers with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Uncommon/Compound Mutations
The National Comprehensive Cancer Network (NCCN) and Taiho Oncology, Inc. are collaborating to offer a new grant opportunity seeking proposals for investigator-initiated
research with Zipalertinib.
NIH Announcements
If you are a Cancer Center member who is interested in applying and receiving grant writing support, please contact Erin Bank.
- Due Jan 23, 2025: NCI Administrative Supplements to Support Cancer Disparity Collaborative Research
- Due Jan 31, 2025: NCI Administrative Supplements for Assessing Capacity to Address Obesity for Cancer Prevention and Control
To view NCI funding opportunities, search here